Cargando…
Inhibition of FAK kinase activity preferentially targets cancer stem cells
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment. VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor t...
Autores principales: | Kolev, Vihren N., Tam, Winnie F., Wright, Quentin G., McDermott, Sean P., Vidal, Christian M., Shapiro, Irina M., Xu, Qunli, Wicha, Max S., Pachter, Jonathan A., Weaver, David T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584283/ https://www.ncbi.nlm.nih.gov/pubmed/28881682 http://dx.doi.org/10.18632/oncotarget.18517 |
Ejemplares similares
-
FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015) -
Breast tumors: of mice and women
por: McDermott, Sean P, et al.
Publicado: (2010) -
FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin
por: McDermott, Sarah C., et al.
Publicado: (2018) -
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
por: Diaz Osterman, Carlos J, et al.
Publicado: (2019) -
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
por: Timbrell, Simon, et al.
Publicado: (2021)